Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$9.55
-15.9%
$9.94
$6.48
$22.79
$1.78B0.55132,173 shs501,403 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$24.34
-2.1%
$25.57
$11.16
$29.95
$1.13B0.52969,554 shs888,688 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$27.41
-0.7%
$25.96
$23.14
$30.93
$3.77B0.461.48 million shs1.06 million shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$33.15
-0.3%
$31.98
$25.53
$40.28
$1.86B0.71477,394 shs1.06 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-15.86%-14.69%-10.93%-21.92%-49.47%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-2.13%-9.79%-2.99%+7.27%-15.98%
Perrigo Company plc stock logo
PRGO
Perrigo
-0.67%+4.18%+1.56%+1.98%-2.92%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-0.33%+2.63%+3.11%+6.35%+26.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4.2448 of 5 stars
3.54.00.04.22.12.50.0
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.2822 of 5 stars
1.21.00.03.92.22.50.6
Perrigo Company plc stock logo
PRGO
Perrigo
4.6162 of 5 stars
2.13.04.23.52.81.72.5
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
1.5467 of 5 stars
1.21.00.04.12.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3.00
Buy$67.50606.81% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.448.65% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0020.39% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.33
Hold$36.008.60% Upside

Current Analyst Ratings Breakdown

Latest PCRX, PRGO, SUPN, and NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
4/11/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$15.00 ➝ $30.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $65.00
3/14/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$90.00
3/13/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/13/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$97.50 ➝ $97.50
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$87.25M20.37N/AN/A$0.69 per share13.84
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$702.77M1.60$3.74 per share6.50$18.74 per share1.30
Perrigo Company plc stock logo
PRGO
Perrigo
$4.34B0.87$5.72 per share4.79$35.19 per share0.78
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$668.00M2.78$1.52 per share21.83$16.87 per share1.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$276.06M-$0.64N/AN/AN/A-180.70%-173.28%-46.31%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$41.96M-$2.28N/A9.47N/A-13.07%13.42%7.19%7/29/2025 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$1.31N/A8.96N/A-3.64%7.38%3.18%8/1/2025 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$1.32M$1.1130.9823.02N/A9.16%7.79%5.67%8/5/2025 (Estimated)

Latest PCRX, PRGO, SUPN, and NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
3/12/2025Q4 2024
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.70$2.25+$4.95$0.03$36.65 million$29.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.23%N/AN/A 23 Years
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest PCRX, PRGO, SUPN, and NKTR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
4.24
4.24
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.51
2.25
1.89
Perrigo Company plc stock logo
PRGO
Perrigo
0.94
2.56
1.77
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
2.20
1.98

Institutional Ownership

CompanyInstitutional Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
5.25%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
220186.10 million177.62 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.22 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,900137.48 million135.47 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
58055.99 million50.08 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$9.55 -1.80 (-15.86%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$9.48 -0.07 (-0.77%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$24.34 -0.53 (-2.13%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$24.34 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Perrigo stock logo

Perrigo NYSE:PRGO

$27.41 -0.19 (-0.69%)
Closing price 06/11/2025 03:59 PM Eastern
Extended Trading
$27.37 -0.04 (-0.15%)
As of 07:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$33.15 -0.11 (-0.33%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$33.15 0.00 (0.00%)
As of 06:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.